Previously, we reported that the administration of a p62/SQSTM1-encoding plasmid demonstrates high safety and clinical benefits for human cancer patients, having also suppressed tumor growth and metastasis in dogs and mouse models. Here we investigated the mechanistic aspects of these effects. In mammary tumors bearing-dogs, p62 plasmid i.m. injections reduced tumor volumes, and reverted tumor grade to less aggressive lesions in 5 out of 6 animals, with one carcinoma switching to benign adenoma. The treatment increased levels of alpha-SMA in stroma cells and collagen 3 in the extracellular matrix, both of which correlate with a good clinical prognosis. p62 treatment also increased the abundance of intratumoral T-cell. To test the role of adaptive immunity, we compared protective effects of the plasmid against B16 melanoma in wild type C57BL/6J mice and in the corresponding SCID strain lacking lymphocytes. The plasmid was only protective in the wild type strain. Also, p62 plasmid amplified anti-tumor effect of adoptive T-cell transfer from tumor-bearing animals to animals challenged with the same tumors. We conclude that the plasmid acts indirectly via re-modeling of the tumor microenvironment, making it more favorable for increased anti-cancer immunity. Thus, the p62-encoding plasmid might be a new adjuvant for cancer treatments.
Introduction
Recent advances in cancer immunotherapy, particularly immune checkpoint blockade therapy, have dramatically changed the therapeutic strategy against advanced malignancies 1 . Yet only a subset of patients demonstrate a positive response to any single therapy.
Moreover, questions relating to how we can maintain durable clinical responses or how we can successfully treat a broader range of cancers by immunotherapy, remain largely unsolved.
Growing evidence suggests that the major barrier to more successful cancer immuno-/chemotherapy is the tumor microenvironment (TME), where chronic inflammation has a predominant role in tumor survival and proliferation, angiogenesis and immunosuppression 2-5 . Over the past decades, our understanding of cancer-related inflammation has significantly evolved, and now we have various therapeutic options tailored to the TME 6 .
These therapeutic strategies include inhibiting inflammatory mediators or their downstream signaling molecules, blocking the recruitment of myeloid cells, modulating immunosuppressive functions in myeloid cells and reeducating the TME 7 . So far, no conclusive studies have been published on stromal content and prognosis in human breast cancer 8 . In an effort to integrate the effects of the TME and patient outcome into pathological criteria, it has been reported that a "reactive" stromal phenotype may predict breast cancer subtypes with an excellent prognosis 9 . Indeed, the lowest risk tumors were more likely to have high intratumoral stromal volume-density and high expression of stromal proteins, including alpha-smooth muscle actin (alpha-SMA), an actin isoform that marks myofibroblasts and cancer associated fibroblasts. Collagens are critical components of the extracellular matrix regulating tumor progression. Although most research on collagen in breast cancer was focused on type I collagen (Col 1) and its pro-carcinogenic effects 10 -12 , new evidence suggest that a related fibrillar type III collagen (Col3) plays an important role in suppressing primary tumor growth and metastasis in a murine model of triplenegative breast cancer 13, 14 . Even though the role of Col 3 as a co-stimulatory molecules for lymphocytes has not yet been investigated, it's known that the extracellular matrix may be both a physical barrier to immune cell infiltration and also provide the substratum essential to the interstitial migration of immune cells 15,16 .
The roles which p62/SQSTM1 plays in cancer and tumor stroma cells remain a subject of active research 17-20 . A human p62-encoding plasmid was originally proposed as a classic DNA vaccine eliciting adaptive immune response against the p62/SQSTM1 protein, which is reported to be over-expressed in the tumors 21, 22 . However, the history of science and medicine bears multiple examples when a new phenomenon was explained based on the mechanisms which were most popular at the time they were observed, later turning out to be secondary or insignificant 23 . Thus, the mechanism of action of the p62 plasmid needs to be reassessed based on the latest observations. Indeed, although treatment with the p62encoding plasmid was reported as therapeutically beneficial in dogs diagnosed with spontaneous breast cancer 24 , it turned out later that unlike in humans, most aggressive canine breast tumors show very low or nil p62 expression 25 . Therefore, eliciting an anti-p62 adaptive immune response cannot be the only effect of the p62-encoding plasmid. Accordingly, we demonstrate that the p62 DNA treatment dramatically impacted the histopathological features of the malignant lesions. Indeed, after p62 DNA therapy compact tumors appear as multi-lobate neoplasms on an intensive reactive vascular stroma 24 . The neoplastic lobules were separated and surrounded by thick bands of inflamed fibrous connective, containing scattered aggregates of macrophages, lymphocytes and plasma cells. An increased number of CD3+ intratumoral T-lymphocytes, (CD3+ TIL) was constantly observed 24 . Taken together, this data raises the question, can a p62 plasmid alter the TME in a way favorable for anti-cancer immune response? 
Materials & Methods

p62 DNA Plasmid
Human p62 (Sqstm1, isoform 1) -encoding plasmid was described elsewhere 41 and produced endotoxin Free-GMP grade by the Aldevron (ND, USA).
Dogs Patients and Treatment
Assessment of the therapeutic effect was performed in the veterinary clinic of the University of Camerino (Italy). A total of six dogs, all females, of different breeds and ages were enrolled in the study ( Table 1) . All of them had histologically confirmed diagnosis of breast carcinoma with WHO stages I-III, progressive disease, and no options for treatment or other treatment options were declined by the owners. The size of tumor was measured every week with a caliper. p62 plasmid was administered i.m. once a weak at the doses of 0.75, 1.5 mg for 3-9 weeks ( Table 1) . During the treatment, blood was collected for biochemical analysis, and the sizes of tumors were measured manually with calipers according to formula π /6 x L x W x H. and the volume of tumor was calculated. Also, the weight and overall well-being of patients were monitored. All the treatments were performed with full consent of the owners.
Tumor Specimens and Immunohistochemistry
Biopsies (Trucut) were performed in all dogs before treatment to establish initial diagnosis.
In 5 out of 6 patients, a second biopsies, along with samples from resected tumors (mastectomy) were collected. Patients # 6 had no mastectomy (see the Text). On day 26 after inoculation, MCA205 tumor-bearing lungs were counterstained with India ink and were enumerated. Lungs with more than 250 nodules were assigned >250 as the maximum number that can be counted reliably.
Results
Anti-tumor activity of p62 DNA plasmid in dogs & histopathological changes
The anti-tumor effects of p62 DNA has been evaluated in a cohort of six (6) dogs bearing simple mammary tumors (Tab. 1). 
p62 DNA induces alpha-SMA and type III Collagen in Tumor Stroma
As we review in the Discussion section, increases in the alpha-SMA and/or Col 3 levels may mean a better prognosis. Both proteins are downregulated by chronic inflammation.
Furthermore, the p62 plasmid reduced chronic inflammation in many mouse models. Thus, we hypothesized that the p62 plasmid would increase alpha-SMA and/or Col 3 levels. Using immunohistochemistry, we observed that p62 DNA administration resulted in significant increases in the expression of stromal alpha-SMA (Fig. 1) coupled with a robust synthesis and deposition of Coll 3 in the ECM, as opposed to a next to basal expression of Col 1 (Fig.2 ). Both Col 1 and Col 3 levels are minimal in a normal mammary gland (Fig.3) . 
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An adaptive immune system is indispensable for the anti-cancer effect of p62 plasmid
In dogs we have observed that p62 treatment increases the number of TILs. However, canine patients with spontaneous tumors cannot be used to learn if the increased TIL abundance is a mechanism of anti-tumor effect of p62 DNA or if it is just a coincidence. To test whether the changes in the tumor stroma induced by the p62-plasmid are sufficient for its anti-tumor effect or if the plasmid primary acts through an adaptive immunity, we compared protective effects of the plasmid in wild-type and severe combined immunodeficiency (SCID) mice. SCID mice have a genetically inactivated adaptive immune system (i.e. lacking T-and B-cells), but maintain an intact innate immune system (i.e., macrophages, NK cells etc). Thus, by comparing the antitumor effect in wt vs. SCID mouse strains one can see if an adaptive immune system is necessary for the anti-tumor effect.
When we challenged SCID mice with B16 melanoma they developed tumors similar to control (wt) syngeneic mice, indicating that the lack of an adaptive immune system does not promote tumor development in this model (Fig.4A ). However, in contrast to wt mice, the p62 plasmid lost its ability to inhibit tumor growth in SCID mice (Fig. 4A) . Furthermore, whereas the p62 plasmid increased survival in wt mice, no such effect was seen in SCID mice (Fig.4B) . Thus, we conclude that an adaptive immune system is required for the anti-cancer effect of the p62 plasmid. Thus, we established that an adaptive immune system is indispensable for the antitumor effect of p62 plasmid. Also, we knew that eliciting a specific anti-p62 adaptive immune response cannot be the only mechanism which the p62-encoding plasmid is using to stimulate anti-cancer adaptive immunity, because the plasmid is active in dogs while canine cancer cells lack their p62 (in contrast to human cells). To bring these two facts together, we hypothesized that the p62 DNA enhances effects of T-cells targeting cancer antigens other than p62 (e.g., acting via immunomodulatory mechanism). If that is correct, the p62 plasmid would increase the efficiency of any therapy generating T-cells targeting tumor associated antigens, e.g. immunotherapies. To test if the p62 DNA vaccine can enhance effects of other immune therapies, we employed a model of adaptive cell transfer where Tcells from tumor-bearing animals are transferred to animals with established tumors (or metastasis). In this model, the p62 plasmid was administered on days 9 and 14 after the animals received the transplantable tumor. This was so it did not have enough time to develop a strong protective anti-p62 immune response which could block or reduce the formation of lung metastasis. Thus, p62 DNA alone shows only a minor effect on lung metastases (Fig. 5A) . At the same time, it amplified the effect of adoptively transferred Tcells on lung metastases (Fig.5B ). 
Discussion
The present translational oncological study was stimulated by the observations made during Despite all the facts linking the extracellular matrix to TILs, it remained to be possible that treatment with the p62 plasmid acts on cancer cells through a mechanism not involving an adaptive immune response. For example, it was reported 13 that reduced Col3 level in heterozygous mice led to increased tumor formation in vivo when the mice were challenged with transplantable breast cancer model. In vitro data from the same paper suggested that the metastatic process is significantly increased when col3 level is reduced. The later phenomenon could not be due to TLC engagement because the in vitro system did not contain lymphocytes.
To establish whether the p62 plasmid indeed acts via an anti-tumor adaptive immune response, we compared the anti-tumor effect of the p62 plasmid in wt and SCID mice strains.
Indeed, if the plasmid acts on the cancer cells directly and/or via a mechanism other than an adaptive immune response then the B16 melanoma administered to the two strains would demonstrate the same sensitivity to the plasmid. In contrast, if the plasmid acts via stimulating/modulating an adaptive immune response, it would be inactive in SCID mice lacking the lymphocytes. This later turned out to be the case. Although p62 DNA has reduced the growth of the subcutaneous B16 melanoma tumor and increased the rate of survival in the wt animals, the plasmid was completely inactive in SCID mice. Thus, we conclude that p62 DNA acts via adaptive immune system.
Considering the fact that, contrary to human tumors, canine breast cancers do not express p62 25 , the plasmid could not act as a classic DNA vaccine encoding p62 as a target tumorspecific antigen. Thus, we hypothesized that the p62 DNA enhances the adaptive immune response to tumor antigens other than p62. To test this hypothesis, we conducted an adoptive cell transfer experiment. T-lymphocytes were isolated from mice challenged with transplantable tumor models and, propagated ex vivo, were administered to animals bearing the same tumors. This led to a significant but incomplete reduction of the number of tumor lesions in the lungs. The murine cancer models are not p62 negative. However, we administered p62 DNA at late time points, so the animals did not have enough time to develop a protective anti-p62 immune response which could influence the formation of tumor lesions in lungs. According to our experience, this type of antigenic affect would take at least 3 weeks. Nevertheless, we observed that treatment with the p62 plasmid enhanced effects of adaptive T-cell transfer.
The fact that the p62 plasmid acts via an adaptive immune response corresponds well to the observations that the plasmid restores sensitivity to chemotherapy. Despite the fact that originally chemotherapeutic agents were selected based their ability to kill rapidly dividing cells, it turned out that many of them act via the immune system (e.g. stimulating immunepresenting cell death or regulating T-regs) 49, 50 . Thus, the result of chemotherapy is a lymphocyte attack on cancer cells. Creating a tumor microenvironment favorable for active TILs makes p62 DNA an equally promising adjuvant for immune-, chemo-and radiation therapies because all of them involve immune response.
Conclusions: We conclude that administering the p62-encoding plasmid changes intratumoral microenvironment and reverts tumor grade. The plasmid can be used as an adjuvant for cancer therapies directly and/or indirectly acting through an immune response (such as chemo-and immunotherapies).
